PTC Therapeutics, Inc.
PTCT
$49.53
-$0.02-0.04%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 806.78M | 900.66M | 900.45M | 927.56M | 937.82M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 806.78M | 900.66M | 900.45M | 927.56M | 937.82M |
| Cost of Revenue | 591.88M | 601.30M | 602.74M | 653.65M | 732.05M |
| Gross Profit | 214.90M | 299.37M | 297.71M | 273.91M | 205.77M |
| SG&A Expenses | 300.91M | 292.52M | 299.95M | 318.90M | 332.54M |
| Depreciation & Amortization | 60.74M | 134.61M | 190.22M | 234.75M | 222.64M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 953.53M | 1.03B | 1.09B | 1.21B | 1.29B |
| Operating Income | -146.75M | -127.76M | -192.45M | -279.74M | -349.40M |
| Income Before Tax | -363.12M | -425.47M | -494.07M | -645.82M | -696.11M |
| Income Tax Expenses | 176.00K | 27.73M | -14.55M | -66.60M | -69.51M |
| Earnings from Continuing Operations | -363.30 | -453.20 | -479.52 | -579.22 | -626.60 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -363.30M | -453.20M | -479.52M | -579.22M | -626.60M |
| EBIT | -146.75M | -127.76M | -192.45M | -279.74M | -349.40M |
| EBITDA | -71.08M | 21.85M | 12.72M | -30.58M | -112.81M |
| EPS Basic | -4.73 | -5.94 | -6.32 | -7.69 | -8.37 |
| Normalized Basic EPS | -1.78 | -2.33 | -2.85 | -3.46 | -3.90 |
| EPS Diluted | -4.73 | -5.94 | -6.32 | -7.69 | -8.37 |
| Normalized Diluted EPS | -1.78 | -2.33 | -2.85 | -3.46 | -3.90 |
| Average Basic Shares Outstanding | 307.35M | 305.64M | 304.09M | 302.10M | 299.33M |
| Average Diluted Shares Outstanding | 307.35M | 305.64M | 304.09M | 302.10M | 299.33M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |